Skip to main content
NRXP
NASDAQ Life Sciences

总统命令加速精神活性药物审批直接惠及NRx Pharmaceuticals

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$2.55
Mkt Cap
$84.322M
52W Low
$1.62
52W High
$3.84
Market data snapshot near publication time

summarizeSummary

NRx Pharmaceuticals宣布，一项新的总统行政命令旨在加速批准用于严重精神疾病的精神活性药物，这直接惠及了该公司。该命令特别指示FDA为具有突破性治疗设计的适当的精神活性药物提供专员国家优先券（CNPV），NRXP已经为NRX-100申请了这一设计。它还促进了现实世界证据和现有的联邦资助临床试验的使用，NRXP计划利用这些来获得其药物的批准。这一发展很大程度上降低了风险，并可能加速NRXP主要药物候选物的监管途径，这一点对于该公司来说至关重要，考虑到其最近在10-K中提到的“持续经营”警告和稀释性融资。这放大了之前的积极的FDA指导，为该公司的产品线提供了强大的后盾。投资者应该关注NRXP的CNPV申请和NRX-100的NDA提交的更新。

在该公告发布时，NRXP的交易价格为$2.55，交易所为NASDAQ，所属行业为Life Sciences，市值约为$8432.2万。 52周交易区间为$1.62至$3.84。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed NRXP - Latest Insights

NRXP
Apr 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
FDA Gives Positive Feedback on NRx Pharma's Preservative-Free Ketamine, Targets Summer 2026 Approval
Sentiment: Positive
View Wiseek Article
NRXP
Apr 20, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Presidential Order to Fast-Track Psychedelic Drug Approvals Directly Benefits NRx Pharmaceuticals
Sentiment: Positive
View Wiseek Article
NRXP
Apr 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
NRx Pharma's Preservative-Free Ketamine Nears FDA Approval with Minor Labeling Feedback
Sentiment: Positive
View Wiseek Article
NRXP
Mar 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Hope Therapeutics, NRXP Subsidiary, Partners with Emobot to Deploy AI-Powered Depression Monitoring
Sentiment: Positive
View Wiseek Article
NRXP
Mar 24, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
7
Stockholders Approve Significant Increase in Annual Incentive Plan Share Reserve
Sentiment: Negative
View Wiseek Article
NRXP
Mar 23, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
8
NRX Pharmaceuticals Reports Going Concern, Massive Dilution, and Key Regulatory Progress in Annual 10-K
Sentiment: Negative
View Wiseek Article
NRXP
Mar 16, 2026, 7:36 AM EDT
Source: Reuters
Importance Score:
9
FDA Confirms Clear, Accelerated NDA Path for NRX-100 by June 2026, No New Trials Required
Sentiment: Positive
View Wiseek Article
NRXP
Feb 23, 2026, 5:00 PM EST
Filing Type: DEF 14A
Importance Score:
8
NRX Pharmaceuticals Seeks Shareholder Approval for Substantial Increase in Equity Incentive Plan Share Reserve
Sentiment: Negative
View Wiseek Article
NRXP
Feb 17, 2026, 9:21 AM EST
Filing Type: 8-K
Importance Score:
9
NRX Pharmaceuticals Secures Clear FDA Path for Full NDA Approval of NRX-100 with Broader Indication
Sentiment: Positive
View Wiseek Article
NRXP
Feb 17, 2026, 9:20 AM EST
Filing Type: 424B5
Importance Score:
9
NRX Pharmaceuticals Announces Highly Dilutive $20M At-The-Market Equity Offering
Sentiment: Negative
View Wiseek Article